Safety and Efficacy Study of LB80380 in the Patients With Lamivudine-Refractory Chronic Hepatitis B
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate the safety and the antiviral activity of ascending
multiple oral doses of LB80380 for 12 weeks in adults with lamivudine-refractory chronic
hepatitis B infection.